I just invested 695.53K in AZN calls with a 77.5 strike expiring on 2025-09-19, as I believe AstraZeneca's growth prospects in the immune checkpoint i...
Read
More
I just invested 695.53K in AZN calls with a 77.5 strike expiring on 2025-09-19, as I believe AstraZeneca's growth prospects in the immune checkpoint inhibitors market and their strong Q4 performance in cancer drug sales may outweigh current legal challenges. The anticipated rebound in 2025 further supports this position.
I just noticed that Astra Zeneca had a nice little dip lately, making it a good time to pick up some shares. With their promising cancer treatment pip...
Read
More
I just noticed that Astra Zeneca had a nice little dip lately, making it a good time to pick up some shares. With their promising cancer treatment pipeline and a solid 2.2% dividend, it feels like a decent investment for the next few months.
I see a solid opportunity with $AZN as I expect it to rebound to the mid to high $70s by early spring. This movement mirrors last winter's trend, and ...
Read
More
I see a solid opportunity with $AZN as I expect it to rebound to the mid to high $70s by early spring. This movement mirrors last winter's trend, and I'm confident in a strong upward potential in the coming weeks.
Given the growing interest in respiratory treatments and AstraZeneca’s market position amidst ongoing scrutiny, I see potential for a short-term uptic...
Read
More
Given the growing interest in respiratory treatments and AstraZeneca’s market position amidst ongoing scrutiny, I see potential for a short-term uptick in AZN shares. With increased demand for respiratory drugs, this presents a timely opportunity for investment before market adjustments occur.